[{"id":"8e871962-d882-425c-bf52-00aaa004787b","acronym":"Keynote 596","url":"https://clinicaltrials.gov/study/NCT02675946","created_at":"2022-01-26T19:54:54.091Z","updated_at":"2025-02-25T16:04:17.687Z","phase":"Phase 1b","brief_title":"CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)","source_id_and_acronym":"NCT02675946 - Keynote 596","lead_sponsor":"Curegenix Inc.","biomarkers":" BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2022-01-26"}]